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Abstract: Altered martial indices before orthopedic surgery are associated with higher rates of
complications and greatly affect the patient’s functional ability. Oral supplements can optimize the
preoperative martial status, with clinical efficacy and the patient’s tolerability being highly dependent
on the pharmaceutical formula. Patients undergoing elective hip/knee arthroplasty were randomized
to be supplemented with a 30-day oral therapy of sucrosomial ferric pyrophosphate plus L-ascorbic
acid. The tolerability was 2.7% among treated patients. Adjustments for confounding factors, such as
iron absorption influencers, showed a relevant response limited to older patients (≥ 65 years old),
whose uncharacterized Hb loss was averted upon treatment with iron formula. Older patients
with no support lost −2.8 ± 5.1%, while the intervention group gained +0.7 ± 4.6% of circulating
hemoglobin from baseline (p = 0.019). Gastrointestinal diseases, medications, and possible dietary
factors could affect the efficacy of iron supplements. Future opportunities may consider to couple
ferric pyrophosphate with other nutrients, to pay attention in avoiding absorption disruptors, or to
implement interventions to obtain an earlier martial status optimization at the population level.
Keywords: iron; anemia; vitamin; dietary supplements; nutraceutical; functional food; orthopedics;
musculoskeletal diseases; older adult; frail; integrative medicine
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1. Introduction
Martial Status in Orthopedic Surgery
In Italy, blood iron is understood to be part of the patient’s martial status (from Italian profilo
marziale: profilo “profile” and marziale “martial”), which is primarily represented by circulating levels
of hemoglobin (Hb), red blood cells (RBCs), transferrin (Tf), and ferritin. Blood values of Hb and/or
RBCs below the normal ranges refer to the unspecific condition named “anemia” (from Greek ναιµ α:
ν- “without” and -α µα “blood”). Anemia is a biochemical sign that can mirror the dysfunction of
hematopoietic organs, but might be also associated to hereditary diseases (e.g., sickle cell disease) or
secondary conditions (e.g., vitamin B12 deficiency in pernicious anemia). The accurate diagnosis of
anemia type should consider diverse blood indices, such as vitamins and inflammatory markers, but the
criterion of Hb < 13 g/dL (♂) or < 12 g/dL (♀) always represents an alarm bell [1,2]. In Orthopedics,
about 17.5% of all subjects undergoing elective hip or knee replacement present iron-deficiency
anemia [3], 20%–30% have uncharacterized anemia [3,4], and over 50% may require preoperative blood
transfusions [5], with trauma patients possibly presenting higher rates. Regardless of etiology, anemia
conditions are associated with wound complications, readmissions, higher transfusions, and mortality
rates [3,6–9]. The lower cytochrome activity grounds altered bactericidal activity of leucocytes [10–13]
and can impair the patient’s immune response. Perioperative blood losses further compromise oxygen
supply, thus creating an imbalance for increased demands that reduces cardiac ejection function [14],
increases the risk of ischemia [15], lengthens skeletal muscles recovery, and impacts on breathing
capacity—in turn, worsening the anesthesia-derived hypoventilation [16]. The required allogeneic
blood transfusions expose institutions to higher costs, thus making it necessary to develop strategies to
mitigate risks [17].
In 2015, the Patient Blood Management (PBM) program was introduced in Italy, with the scope of
ensuring the appropriateness in the management of blood resources. The first pillar of this approach
comprises the preoperative optimization of hematopoiesis [18]. In 2019, we proposed the integration
of the hospital standard of care in Orthopedics with a Preoperative Optimization Clinic (POC) [9].
In this health facility, patients enlisted for major orthopedic surgery could undergo a program for
correcting anemia conditions, thus ameliorating outcomes. Nowadays, an opportunity for anemia
correction could be exploited during the anesthesia evaluation 30 days prior to surgery, when clinical
and surgical needs are considered [19]. Most anemia types can be corrected through parenteral iron
that bypasses the step of intestinal absorption, thus assuring the repletion of body storages often upon
one-time administration. Nevertheless, this procedure is not without risk and requires specialized
personnel with a dedicated ambulatory where patients can be monitored. An option for martial status
optimization could be the use of oral iron supplements [20–23]. Different formulas have been available
since decades, with iron salts (e.g., ferrous sulphate [24] and ferric pyrophosphate [25]) being widely
used. Different pharmaceuticals may be preferred according to the specific setting of use, such as
polysaccharide-iron complexes (e.g., ferric polymaltose [26]) for pregnant women or even microspheres
of pure iron (i.e., carbonyl iron) for food fortification. However, gastrointestinal side effects were
often reported, together with poor absorption and intestinal inflammation [27]. To avoid these issues,
a novel formula consists of ferric pyrophosphate that is surrounded by a sucrosomial matrix made of
phospholipids and sucrester: within this vehicle, iron absorption is maximized and the metal never gets
in contact with mucosal cells, thus greatly increasing gastrointestinal tolerability. Nonetheless, blood
tests are currently still questionable in identifying patients who should be preoperatively optimized,
and false-positive results might increase hospital visits and augment patient’s anxiety [28]. Therefore,
a population medicine approach may be more practical. Following PBM Italian indications and
previous literature evidences, we planned a preoperative intervention to observe the efficacy and
tolerability of an oral iron therapy in ameliorating the martial status of patients undergoing hip or
knee surgery at IRCCS Orthopedic Institute Galeazzi, this intervention being one of the very first steps
in building the future POC [9,29].
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2. Materials and Methods
2.1. Study Design and Participants
The study was conducted at IRCCS Orthopedic Institute Galeazzi of Milan (Italy). The research
was planned as an open-label randomized controlled trial on humans with no placebo, to study
the efficacy of a dietary supplement of sucrosomial ferric pyrophosphate plus L-ascorbic acid in
ameliorating the martial status of patients undergoing hip or knee prosthetic surgery. The recruitment
period was set between January 2018 and June 2019, with screening and enrolment being conducted
among consecutive patients referring to a single surgical unit during the anesthesia evaluation 30 days
prior to surgery. A modification of Hb before and after treatment was set as primary outcome variable
(efficacy), while the dietary supplement tolerability was set as secondary outcome (safety). A sample
size of 82 patients comprising drop estimation was calculated to obtain a significant primary outcome
(+ 0.80 g/dL of Hb after treatment). We screened patients who were candidates for first elective
total hip or knee replacement with at least 1 months’ notice. Eligibility criteria were Caucasian race,
years of age between 18–80, male or female genders, and a predicted operative risk score of the
American Society of Anesthesiologists (ASA) ≤ 3. Exclusion criteria were neuropsychiatric disorders,
orthopedic revisions, use of supplements, adverse reactions to supplements, iron disorders, myelo-
or lympho-proliferative diseases, chronic kidney disease, tumors. On the same day of signing of the
informed consent, patients were randomized by using an online tool that gives a random assignment
(https://random.org/) between two groups: the control group followed the hospital standard of care
with no placebo, whereas the dietary supplement was prescribed to the intervention group. According
to the study protocol, about 30 days had to pass between the randomization and the day of surgery.
Blood samples were collected after the informed consent signature (baseline, T0) and the day before
surgery (T1). Patients were also monitored for complications a few days in the hospital ward (G0, G1,
and G2). The San Raffaele Ethics Committee of Milan (Italy) approved and authorized the protocol
(code: 158/int/2017) on February 8th 2017, in compliance with the current Italian and international
regulations governing the involvement of humans in clinical trials. The study was registered on a
dedicated website (https://clinicaltrials.gov/) that assigned the code NCT04078880. The dataset with
all demographic, clinical, and laboratory data that have been reported in this paper will be provided
during the review process.
2.2. Intervention and Biochemical Analyses
The intervention group was supplemented daily with 1 capsule of 30 mg of iron plus 70 mg
of L-ascorbic acid. Metallic taste, nausea, gastric distress, and dark stools are symptoms that are
supposed to be avoided by using this pharmaceutical formula. For comprehensive insights into
the pharmaceutical formula, see Appendix A. To monitor the martial status, laboratory tests were
decided on the bases of logistics. Whole blood was collected before surgery at T0 (−30 days) and at
T1 (day before/of surgery) and was processed within 3 hours from withdrawals on fully-automated
analyzers. Ethylenediaminetetraacetic acid (EDTA) tubes (Becton Dickinson, Italy) and Sysmex XN
(Dasit, Italy) were used for blood count and differential, which comprised Hb, RBCs (net count of
erythrocytes), mean corpuscular volume (MCV, average size of a single erythrocyte), mean corpuscular
hemoglobin (MCH, average amount of Hb inside a single erythrocyte), and mean corpuscular
hemoglobin concentration (MCHC, average concentration of Hb inside a single erythrocyte). Blood
samples in clot activator tubes (Becton Dickinson, Italy) were centrifuged (2600g at 4 ◦C for 15 min.).
Serum iron (chromogen Ferene), Tf (immunoturbidimetric assay), Tf saturation (sat), and ferritin
(chemiluminescence immunoassay) were measured on Architect ci 8200 analyser (Abbott, Italy). Tf is
the transporter of iron and Tf sat is calculated as the percentage of binding sites on all Tf molecules
occupied with iron. Ferritin is the serum protein that delivers iron to cells and reflects the amount of
stored iron. See Appendix B for detailed descriptions and significances of blood indices.
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2.3. Statistical Analyses
Adherence to the dietary supplement was strictly monitored and patients were asked to bring back
empty boxes at T1. For this reason, data have been analyzed as originally allocated after randomization
(intention-to-treat analysis). The Shapiro–Wilk test has been applied for distinguishing between
normally distributed and skewed values. The continuous variables of years of age, MCV, MCH, iron, Tf,
Tf sat, and ferritin have been analyzed as skewed, whereas Hb, RBCs, and MCHC have been analyzed
as normally distributed values. All tests have been performed by using SPSS 22 and 2-tailed tests.
Data between groups have been compared at T0 by using the independent sample t-test for normally
distributed values or the Mann–Whitney U test for skewed values in order to state the absence of
differences between groups, thus verifying the success of randomization. To investigate the efficacy of
the dietary supplement, red blood cell indices and iron tests at T1 have been confronted to observe any
group difference, which might reflect the efficacy of the dietary supplement in modifying the martial
status of recruited patients. Unadjusted data have been compared by using the independent sample
t-test or the Mann–Whitney U test. In order to identify if demographic variables could confound
the response to treatment, first a Pearson’s correlation and then a linear regression analysis has been
used to investigate the existence, direction, and strength of the association with our primary outcome
variable. Paired samples t-test has been used to verify the treatment effects on Hb in subgroups of
patients adjusted for randomization and specific variables. To investigate the safety of the dietary
supplement, the occurrence of adverse effects associated with oral iron was monitored few days after
surgery and reported as a rate of events comprising nausea, vomiting, gastric pain, constipation or
diarrhea onsets.
3. Results
A total of 82 patients undergoing elective hip or knee replacement were selected and recruited,
with nine patients counted as drop outs at trial completion. Baseline RBCs indices and iron profiles
have been reported in Table 1.
Table 1. Biochemical markers of martial status of study patients who were recruited about 30 days
prior to hip or knee replacement during preoperative anesthesia evaluation.
Randomization Step (Baseline, T0)
(n = 73)
Prevalence out of Ref. Val.
n (%)
♂(n = 30) ♀(n = 43) ♂ ♀
Hb (g/dL) 15.0 ± 1.3 (11.7–17.0) 13.5 ± 1.3 (9.6–16.1) 2 (6.7) 3 (6.9)
[ref. val.] [13.7–17.5] [11.2–15.7]
RBCs (106/µL) 4.9 ± 0.4 (3.8–5.5) 4.8 ± 0.5 (3.8–6.1) 7 (23.4) 8 (18.6)
[ref. val.] [4.63–6.08] [3.93–5.22]
MCV (fL/cell) 89.8 (88.2; 92.5) 88.4 (85.5; 90.8) 8 (26.7) 7 (16.3)
[ref. val.] [79.0–92.2] [79.4–94.8]
MCH (pg/cell) 30.5 (29.7; 31.0) 29.0 (27.5; 30.2) 2 (6.7) 7 (16.3)
[ref. val.] [25.7–32.2] [25.6–32.2]
MCHC (g/dL) 33.9 ± 0.9 (32.6–35.6) 32.7 ± 1.0 (30.7–34.8) 0 (0.0) 12 (27.9)
[ref. val.] [32.3–36.5] [32.2–35.5]
Iron (µg/dL) 76.5 (65.5; 89.0) 67.0 (57.0; 83.5) 2 (6.7) 2 (4.6)
[ref. val.] [31–144] [25–156]
Tf (mg/dL) 247.0 (227.3; 256.3) 268.0 (239.0; 296.0) 2 (6.7) 1 (2.3)
[ref. val.] [163–344] [180–382]
Tf sat (%) 21.5 (18.3; 25.8) 17.0 (13.0; 23.0) 11 (36.7) 14 (32.6)
[ref. val.] [20–50] [15–50]
Ferritin (ng/mL) 190.5 (125.5; 313.3) 75.0 (39.5; 125.0) 12 (40.0) 4 (9.3)
[ref. val.] [22–275] [5–204]
Normally distributed values have been reported as means ± SD (min-max). Skewed values have been reported
as medians (Q1; Q3). Abbreviations: ref. val. = reference values according to our laboratory, Hb = hemoglobin,
RBCs = red blood cells, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean
corpuscular hemoglobin concentration, Tf = transferrin, Tf sat = transferrin saturation.
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Reasons for the drops were the following: two postponements of surgery, one unreliable to
treatment, five missing blood withdrawals, one experiencing gastric distress to treatment (tolerability
outcome). According to the World Health Organization (WHO) criterion (Hb cut-offs of 12–13 g/dL),
about 8.2% of our patients suffered from anemia at baseline. 20.5% of all subjects were anemic with
the Hb cut-off of 13 g/dL for both genders, and 6.8% according to our Hb laboratory ranges (♂:
13.7−17.5, ♀: 11.2−15.7). The mean age of the patients was 67.3 ± 8.6 years (range: 49−99) and the
study involved 30 males and 43 females, grouped into 28 adults (< 65 years old) and 45 older adults (≥
65 years old). The accuracy of randomization has been evaluated by confronting baseline (T0) data
between the intervention and control groups: no significant differences have been observed for age
(p = 0.356), Hb (p = 0.403), RBCs (p = 0.483), MCV (p = 0.608), MCH (p = 0.800), MCHC (p = 0.904),
iron (p = 0.476), Tf (p = 0.402), Tf sat (p = 0.774), or ferritin (p = 0.318). Females had a mean Hb at
T0 of 13.5 ± 1.3 g/dL (9.6; 16.1) and males had a mean of 15.0 ± 1.3 g/dL (11.7; 17.0). A total of 36
patients were randomized to the control group and 37 to the intervention group. After about 30 days
of treatment (T1), the biochemical markers of martial status in the intervention group showed no
statistically significant differences compared to the parameters in the control group. Details of means
and medians of changes in blood values have been reported in Table 2.
Table 2. Biochemical markers of martial status in patients randomized to control group (C) or treatment
group (I) with 30 mg of sucrosomial ferric pyrophosphate and 70 mg of L-ascorbic acid daily during
30 days prior to hip or knee surgery.
Randomization
Step
(baseline, T0)
Preoperative Step
(after 30 days, T1) T0 p-Values * T1 p-Values *
Hb (g/dL) C 14.3 ± 1.3(11.7–16.4)
14.1 ± 1.2
(11.2–15.9) p = 0.403 p = 0.259
I 14.0 ± 1.7 (9.6–17.0) 13.8 ± 1.5(10.7–16.6)
RBCs (106/µL) C 4.9 ± 0.4 (3.8–5.7) 4.8 ± 0.4 (3.7–5.4) p = 0.483 p = 0.584
I 4.8 ± 0.6 (3.8–6.1) 4.7 ± 0.5 (3.6–6.0)
MCV (fL/cell) C 89.5 (86.3; 91.5) 88.1 (86.1; 92.3) p = 0.608 p = 0.825
I 89.0 (86.1; 92.0) 89.5 (85.3; 91.2)
MCH (pg/cell) C 30.0 (28.5; 30.6) 30.0 (28.5; 30.9) p = 0.800 p = 0.627
I 29.7 (28.5; 30.7) 29.7 (28.5; 30.9)
MCHC (g/dL) C 33.2 ± 1.0(30.8–35.5)
33.5 ± 1.0
(31.9–35.6) p = 0.904 p = 0.906
I 33.2 ± 1.2(30.7–35.6)
33.5 ± 1.4
(30.5–37.0)
Iron (µg/dL) C 74.0 (64.0; 85.0) 87.0 (66.0; 107.0) p = 0.476 p = 0.830
I 69.0 (61.0; 83.0) 94.0 (66.0; 110.0)
Tf (mg/dL) C 258.0 (234.8; 287.0) 256.5 (229.8; 291.8) p = 0.402 p = 0.559
I 253.0 (228.0; 285.0) 248.0 (229.0; 274.0)
Tf sat (%) C 20.0 (15.0; 23.0) 22.0 (16.8; 30.3) p = 0.774 p = 0.515
I 20.0 (16.0; 23.0) 24.0 (17.0; 32.0)
Ferritin (ng/mL) C 129.0 (75.0; 218.0) 151.5 (68.8; 229.0) p = 0.318 p = 0.256
I 100.0 (51.0; 181.0) 94.0 (51.0; 161.0)
* The significant statistical difference between groups was calculated by using the independent sample t-test or
the Mann–Whitney U test for normally distributed or skewed values, respectively. All tests were performed by
using SPSS 22 and 2-tailed tests. Normally distributed values have been reported as means ± SD (min-max).
Skewed values have been reported as medians (Q1; Q3). Abbreviations: Hb = hemoglobin, RBCs = red blood cells,
MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin
concentration, Tf = transferrin, Tf sat = transferrin saturation.
We hypothesized that age could affect the response to treatment. We analyzed data considering
the cut-off of 65 years and the percentage change from baseline of Hb (∆Hb). Of note, the younger
group (n = 28) started with a mean Hb of 14.7 ± 1.3 g/dL (11.9; 17.0) and the older group (n = 45)
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started with a mean of 13.7 ± 1.4 g/dL (9.6; 16.6). Among older adults, the treatment variable was fairly
correlated to ∆Hb (R = 0.348; p = 0.019), with regression analyses revealing a positive linear association
between age and response to treatment (B = 3.522; 95% CI: 0.604 to 6.441; p = 0.019).
Indeed, older adults who were randomized to the intervention group had a mean increase from
baseline of 0.7 ± 4.6% (p = 0.627), compared to the control group that lost −2.8 ± 5.1% (p = 0.014) of
baseline Hb. A statistically significant difference between groups was found in the levels of Hb at T1
(p = 0.019). In our cohort, patients over/equal 65 years showed to regularly lose significant points of
Hb within 30 days prior to surgery (from 13.8 ± 1.1 to 13.4 ± 1.0 g/dL), with daily oral supplementation
of 30 mg of sucrosomial ferric pyrophosphate and 70 mg of L-ascorbic acid being effective in prevent
the loss (from 13.6 ± 1.7 to 13.7 ± 1.6 g/dL). The different response to treatment among older adults has
been reported in Figure 1.
Figure 1. Area charts of hemoglobin changes, expressed as a percentage from baseline, in the subgroup
of older adults within 30 days prior to hip or knee surgery. Control group: blue. Intervention group:
red. The treatment consisted of daily supplementation of 30 mg of sucrosomial ferric pyrophosphate
and 70 mg of L-ascorbic acid. In the y-axis is the percentage change in hemoglobin (%), whereas in the
x-axis is the age of subjects. The oldest subjects in the control group appear to lose more hemoglobin
than their youngest counterparts, but the oldest are also those that respond the more to treatment in
the red group. In the control group, the cumulative absolute decrease in hemoglobin from baseline was
−11.7 g/dL and in the intervention group was −4.6 g/dL.
The treatment variable showed statistically significant effects also in the group of adults (R =−0.480;
p = 0.010), with an inverse linear association (discrete, 0 = control, 1 = intervention; B = −4.736; 95% CI:
−8.222 to −1.251; p = 0.010). Explicitly, adults who were treated had a mean decrease of −3.1 ± 5.0%
(p = 0.024) and those in the control group had no differences (p = 0.194). This latter ambiguous effect
was exploited after adjusting for gastrointestinal diseases and drugs that counteract the production
of acid in the stomach. Within the whole study cohort, only three subjects reported to suffer from
chronic intestinal disorders or had gastrointestinal surgeries (one gastric bypass, one chronic gastritis,
and one gastroesophageal reflux disease (GERD)), and all were casually part of the treated group of
adults. A fourth patient in the same subgroup used chronic antiacid medications, and they overall had
no response to treatment. Excluding these four patients from the analysis, no more differences were
observed in the group (p = 0.090). Of note, the other seven patients sparse within other subgroups
reported to chronically use antiacids, but no differences in the results were observed after adjustments.
In our cohort, control patients less than 65 years of age maintained serum Hb levels within 30 days
prior to surgery. If adult patients suffered from gastrointestinal disease or chronically use antiacid
medication, they might encounter a significant loss irrespective of concomitant oral supplementation
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with 30 mg of sucrosomial ferric pyrophosphate and 70 mg of L-ascorbic acid per day. Biochemical
markers of martial status in the subgroup of older patients were reported in Table 3.
Table 3. The percentage change from baseline of biochemical markers of martial status in patients
over/equal 65 years old randomized to control group (C, n = 23) or treatment group (I, n = 22) with
30 mg of sucrosomial ferric pyrophosphate and 70 mg of L-ascorbic acid daily during 30 days prior to
hip or knee surgery.
30-Days Changes (T1-T0)% p-Values *
C I
∆ *Hb −2.8 ± 5.1 0.7 ± 4.6 p = 0.019
∆RBCs −3.3 ± 5.7 0.0 ± 4.8 p = 0.041
∆MCV −0.2 −0.1 p = 0.923
∆MCH 0.3 0.0 p = 0.708
∆MCHC 0.8 ± 2.0 1.1 ± 4.5 p = 0.806
∆Iron 24.2 40.8 p = 0.709
∆Tf −0.2 0.9 p = 0.904
∆TIBC 20.0 42.6 p = 0.754
∆Ferritin 7.3 1.7 p = 0.952
* Data has been reported as the mean percentage change from baseline values. ** The significant statistical
difference between groups was calculated by using the independent sample t-test or the Mann–Whitney U
test for normally distributed or skewed values, respectively. All tests were performed by using SPSS 22 and
2-tailed tests. Abbreviations: Hb = hemoglobin, RBCs = red blood cells, MCV = mean corpuscular volume,
MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, Tf = transferrin,
Tf sat = transferrin saturation.
4. Discussion
In line with previous evidences [30], our cohort presented low rates of anemia (non-anemic
patients: 91.8%) at preoperative anesthesia evaluation, but our eligibility criteria could have excluded
the most complicated patients with martial status alterations. Patients were supplemented with an
iron formula that had former evidence of efficacy [25], but—as previously described—even treatments
supported by research evidence should be confirmed upon each new context of use. After 30 days of
oral iron plus L-ascorbic acid therapy, no significant changes in the martial status were observed after
treatment. The overall tolerability was 2.7% among treated patients (1 in 37). Although the subgroup
of adults younger than 65 years of age did not respond to treatment and maintained their Hb levels
approaching the day of surgery, older adults over/equal 65 years experienced an uncharacterized
Hb loss. These significant reductions were averted upon treatment with iron formula. The martial
status in adults appears to be more conservative, but diseases of the gastrointestinal system or past
resection surgeries can expose patients to significant disturbances, which cannot be defused through
standard iron supplementation. In the past, it was suggested that preoperative programs, such as
exercise therapy [31], could be more meaningful and cost-effective if targeted to specific subpopulations.
However, this may be not the case for dietary supplements. As a consequence, we choose a population
medicine approach of “treating all instead of mass screening and then treating few” for the following
reasons: I) Biochemical markers are not so sensitive and specific in discerning iron-deficiency anemia
from other anemia types since also the subjects’ nutritional status and functional ability matter [9].
II) Normal baseline values may be rather irrelevant compared to the individual increase after iron
therapy, which could provide more oxygenation to tissues even to healthy individuals who would
have been excluded by treatment algorithms [20] because of normal Hb values (baseline Hb in older
adults: 13.8 ± 1.1 g/dL). III) The set of rules for detecting, evaluating, and managing preoperative
anemia might be unsuitable for high-performance centers, such as our IRCCS Orthopedic Institute
Galeazzi that perform over 4000 interventions of major orthopedic surgery per year [9]. Screening all
patients for martial and inflammatory status, vitamin profile, and the referral to gastroenterologists or
nephrologists for individual treatment may be optimal, but not cost-effective.
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Concerning the second reason, we undeniably took advantage in supplementing non-anemic older
patients. In fact, among the control group of 23 older adults that encountered a significant reduction in
Hb levels from baseline, over 95% resulted to be non-anemic at baseline, but lost a significant amount
of Hb nevertheless. Using oral iron formulas in this group could have prevented the worsening of
martial status. Older patients had a mean Hb at T0 that was lower than the younger group and this
could certainly reflect lesser physiological reserves with lower ferritin deposits and higher demands for
iron transport. Adults had ferritin levels of 121.5 ng/mL and Tf levels of 258 mg/dL, while older adults
had 86.0 ng/mL and 253 mg/dL, respectively. We can hypothesize that our older subgroup could suffer
a hybrid form of uncomplicated iron deficit with no acute inflammatory response [2]. Iron supply to
erythropoiesis could have been becoming insufficient and Tf could have been upregulated to increase
iron transport. Upon iron deficiency, first ferritin reduces and then Hb [32,33]. In this borderline
condition, we may suppose an impairment of oxygen supply that could affect the functional ability
nevertheless. The highest iron demands for erythropoiesis make a prolonged iron deficiency reflected
by in low RBCs, and upon adequate iron integration, new erythrocytes take advantage of a positive
iron pool (Table 3). Since it is a common thought that liver iron represents the main source upon
bleeding, an increase in ferritin, reflecting higher iron deposits, would have been desirable. However,
the higher median increase from the baseline of circulating µg of iron and Tf sat—even if not statistically
significant—could have been enough to deliver more iron to the bone marrow and, in turn, augment
RBC production.
We observed that gastrointestinal conditions, such as gastric bypass, gastritis, or GERD, cause adult
patients to ineffectively absorb dietary iron. Other illnesses that certainly influence iron homeostasis
are Helicobacter pylori infection and peptic ulcer disease [34]. Concerning medications, they are factors
being part of the vast group of “iron absorption influencers”. These influencers can be disruptors (i.e.,
negative effectors) or enhancers (i.e., positive effectors), and are of great importance in the management
of oral iron therapies: in fact, the metal easily changes its state of oxidation to form coordination
complexes with other atoms capable of donating electrons, and absorption influencers can frustrate or
potentiate the planned therapy. For instance, over 10% of our cohort patients reported to chronically
use antacid medications, which are known to substantially reduce iron absorption. Other negative
effectors on iron absorption are mainly of dietetic origin and can form insoluble salts in the stomach,
such as oxalic and phytic acids, or compete for absorption through SLC11A2, such as manganese, zinc,
and lead [35]. Furthermore, dietary calcium might inhibit the absorption of both heme and non-heme
iron [36], whose interference is also experienced by plants [37], but even the food matrix itself might
impede the availability [38]. Although we did not monitor the dietary intakes of disruptors or iron in
our patients, which may represent a possible confounder in the interpretation of our results, future
researchers may consider conducting dietary monitoring in their future studies. Indeed, recommended
iron intakes for the lowest iron availability can even be set at 27.4 mg/die for men and 58.8 mg/die
for women [39], considering the lowest observed adverse effect level being 70 mg/die [40]. In this
study, we used a pharmaceutical formula that contained an absorption enhancer: the L-ascorbic acid.
This water-soluble vitamin has a reducing potential able to prevent the oxidation of neighboring
molecules. Despite only a small fraction of ingested vitamin C being absorbed, it is known to exert
positive pharmaceutical actions in the lumen of the stomach and small intestine by reducing non-heme
Fe3+ to Fe2+ and acting as a weak chelator, similarly to citric and lactic acid [41], to help solubilizing
the metal [42]. In cells, L-ascorbic acid can promote the release of iron from deposits [43]. Of note,
other positive effectors on iron absorption are fructose, copper [44], vitamin A, and β-carotene [45].
Poor dietary intake of bioavailable iron and L-ascorbic acid may aggravate martial status
alterations in older adults undergoing elective orthopedic surgery. Even if there was no anemia
condition, it would be particularly relevant to apply a population medicine approach to sustain
each patient’s needs, and oral iron therapies are usually the first-line treatment for uncomplicated
anemia. However, dietary supplements are often misused by patients [46,47], mainly because of their
availability, ease of administration, and relatively low costs [48]. Dietary supplements do not lack in
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adverse effects [46,47], and intelligent interventions are uncommon and often non-adapted to age, sex,
or lifestyle behaviors—such as inhabitation altitude or smoking habits [1]. The complexities of different
pharmaceutical formulas to be integrated and the extent of absorption influencer interferences are often
missed, possibly leading to ineffectiveness [49,50] or side effects [51–53]. The intravenous route may
be chosen when patients do not tolerate oral administration or when the supplement has no effects, or
when compliance to oral therapy is dubious [54]. In fact, the efficacy of oral formula in optimizing the
martial status often requires daily administration whereas a single-dose of intravenous iron may be
sufficient [55]. Our formula with iron plus L-ascorbic acid was effective in older adults, but perhaps
more satisfying results would have been obtained if our patients had also been supplemented with
cobalamin, folate, and vitamin A. It would also have been interesting to monitor more accurately
iron markers, such as the concentrations of erythrocyte protoporphyrin (EP) and soluble transferrin
receptors (sTfRs) [56], but also inflammatory parameters.
5. Conclusions
Humans rely on three mechanisms for iron incorporation: intestinal passage, ferritin allocation, and
erythrocytes cycle. Despite these biological strategies, humans commonly suffer from iron deficiency
syndromes. Poor oral iron intake and bioavailability, aging process, co-existing conditions, and
absorption disruptors affect iron homeostasis. Literature evidences and laws recommendations stress
the need to improve martial status before orthopedic surgery and this integration can be exploited
in the orthopedic POC. However, no pragmatic connection exists between guideline statements
and their effectiveness, and the identification of deficient patients relies on often-hardy applicable
algorithms. We supported a population medicine approach, which has already been proved to be
effective even in the most complicated patients [57], and obtained remarkable results dependent on
age, gastrointestinal conditions, and medications. Instead of choosing patients that should or should
not undergo oral iron supplementation, future POC may sustain a basic “iron prophylaxis” for all
orthopedic patients. The concept of timing is extremely relevant, either within the same day or through
alternative days, with important differences in tolerability and absorption [58,59]. Alternative solutions
at the population level might be required in the near future to correct anemia long before surgery. For
instance, the American National Heart, Lung, and Blood Institute defines healthy eating changes, and
not oral iron supplementation, as first-line treatments for mild to moderate iron-deficiency anemia [60].
Managing a nutritional supplementation with iron sources is pertinent for the proper care of orthopedic
patients that face important blood losses, with the key factor for success being always the same: a
constructive multidisciplinary team capable to bring to light any relevant aspect to guarantee the entire
orthopedic population a medicine as precise as possible [9,61].
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Appendix A. Dietary Supplement
Our study patients were supplemented with a daily capsule containing 30 mg of iron in the ferric
pyrophosphate form surrounded by a sucrosomial matrix made of phospholipids and sucrester (SiderAl
Forte, PharmaNutra). The iron coordination entity is composed of Fe3+ cations and diphosphate4-
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anions in a 4:3 ratio. The sucrosomial matrix is stabilized by tricalcium phosphate bindings that reduce
lipid mobility [62], with other ingredients being incorporated, such as a pre-gelatinized rice starch,
glucose syrup, and milk proteins, collectively forming the “sucrosome”. In particular, the sucrester
is a surfactant derived from the esterification of fatty acids with sucrose (sucrose esters) and it
allows the formula to be gastro-resistant and to be highly absorbed in intestines [63]. The dietary
supplement that was used in this research also contained different components classified as bulking
agents (microcrystalline cellulose, edible gelatine), anti-oxidant (L-ascorbic acid), anti-caking agents
(hydroxypropyl methylcellulose, magnesium salts of fatty acids, silicon dioxide), and coloring agent
(titanium dioxide). The increased absorption of this formula was reported to facilitate the enteric
transport through paracellular and transcellular routes [64]. In particular, it was shown that the
sucrosome is mostly absorbed as a vesicle-like structure through endocytosis-mediated cellular uptake,
bypassing the conventional iron absorption pathway [65]. Immune cells may be involved in the iron
acquisition from sucrosomes. In fact, resident macrophages in the intestines, which are known to
stabilize the enteric barrier function through intraepithelial projections [66], could incorporate the
sucrosome, obtain iron, and subsequently release it into the plasma when needed. Indeed, red pulp
macrophages are known to be involved in the clearance of aged RBCs and iron recycling. These
resident immune cells in the gut may even act as transient iron deposits [65]. M cells of Peyer’s patches,
which comprise absorptive cells and hollows that enfold defensive components, may also have a role
in sucrosome absorption. In fact, these cells usually transfer microbes or other particles from the
luminal face to the lamina propria where are resident immune cells, and their mediated pathway for
sucrosome absorption could ultimately involve the taking up by macrophages [63], thus fulfilling the
abovementioned roles.
Figure A1. Schematics of the formula that was used in the research study and the suggested mechanisms
of intestinal absorption. Absorption starts with passive transport by enterocytes or specialized epithelial
cells of the mucosa-associated lymphoid tissues (M cells), and concludes with macrophage degradation
and storage.
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Appendix B
Table A1. Blood-based indicators of martial status.
Marker Description Ref. val. Significance
Hb
Assembly of four globular polypeptide chain, with each one being
associated with a prosthetic heme group that contains an atom of
iron either in the ferrous or in the ferric state. The four oxidized ion
atoms in Hb carry four oxygen molecules.
♂[13.7–17.5 g/dL]♀[11.2–15.7 g/dL]
Hb concentration in blood is a measure for anemia. Low serum
values reflect low functional iron when there are no concurrent
infective/inflammatory disorders or other micronutrient deficits,
such as vitamin A or B group.
RBCs
Anucleated biconcave disks with an aphospholipid bilayer. They
lack most organelles and appear with a central pallor and
surrounding warp filled with Hb. The deformable shape allows the
traversing of the smallest capillaries.
♂[4.63–6.08 106/µL]♀[3.93–5.22 106/µL]
They reflect the intensity of erythropoiesis when there are no
concurrent B vitamin deficiencies, or diseases of kidneys, liver, and
thyroid. Low RBCs can mirror an iron depletion.
MCV
Average size/volume of a red blood cell. Calculated as the ratio of
hematocrit, which measures the volume percentage of RBCs, to RBCs
concentration. The higher the MCV the greater the average
size/volume of erythrocytes.
♂[79.0–92.2 fL/cell]♀[79.4–94.8 fL/cell]
Indicative of a correct erythropoiesis. When bone marrow lacks a
proper iron supply, MCV is low and RBCs are microcytic. A
deficiency of cobalamin or folate results in higher MCV, which is a
condition named macrocytic anemia.
MCH
Indirect index calculated as the ratio of Hb to RBCs. Haemoglobin
molecules in erythrocytes are located in the periphery and surround
a central pallor. The more extensive the central pallor the lesser Hb is
contained (left erythrocyte).
♂[25.7–32.2 pg/cell]♀[25.6–32.2 pg/cell]
MCH value closely parallels the value of MCV. Defects in nuclear
maturation, such as in megaloblastic anemia, result in high values
of MCH.
MCHC
Indirect index calculated as the ratio of Hb to the volume percentage
of RBCs. The value of MCHC is increased in spherocytosis as
erythrocyte assume a spherical shape because of the loss of
membrane (erythrocyte on the right).
♂[32.3–36.5 g/dL]♀[32.2–35.5 g/dL]
It correlates Hb with RBCs volume. Low values can reflect
micronutrient deficiencies. When no genetic disease or hemolysis is
present, high values are mostly artefact (lipemia), because RBCs
cannot contain more Hb than normal.
Iron
The amount of the metal that is circulating in blood, primarily bound
to proteins, such as Tf and ferritin. A slightest part is non-transferrin
bound iron (NTBI) and has capacity to generate highly reactive
free radicals.
♂[31–144 µg/dL]♀[25–156 µg/dL]
The highest serum levels can result from intravenous iron or genetic
diseases, whereas lowest concentrations can be found in anemias for
inflammation or chronic diseases.
Tf
A single polypeptide chain and two carbohydrate chains forms Tf.
When no iron is bound, the protein is called apotransferrin. Tf binds
a maximum of two atoms of ferric iron for its solubilisation and
reactiveness reduction.
♂[163–344 mg/dL]♀[180–382 mg/dL]
It transports iron and reflects, similarly to its receptors on RBCS, the
demand of iron. If there are no other reasons for abnormal
erythropoiesis, its serum levels increase when iron stores are
exhausting. It is a negative acute-phase protein.
Tf saturation
The binding sites on all Tf molecules occupied with iron. It is
calculated as the ratio of serum iron to Tf or serum iron to total iron
binding capacity (TIBC), the latter being the total amount of blood
iron that can be bound by proteins.
♂[20–50%]♀[15–50%]
It provides information, similarly to Tf, about the adequacy of iron
supply to meet cellular requirements. High degrees of saturation
identify patients at risk of iron overload.
Ferritin
A 24-units globular protein with both light and the heavy chains that
takes up to 4300 iron atoms to be deposited in its core of few nm. The
form of iron deposit consists of crystals of ferric hydroxides
and phosphates.
♂[22–275 ng/mL]♀[5–204 ng/mL]
Its serum levels represent a small fraction of the body’s ferritin pool.
Low serum values reflect a depletion of iron stores when there are no
concurrent infections or vitamin C deficits. It is a positive
acute-phase protein.
Abbreviations: Ref. val. = reference values for males and females, Hb = hemoglobin, RBCs = red blood cells, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin,
MCHC = mean corpuscular hemoglobin concentration, Tf = transferrin, Tf sat = transferrin saturation.
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